濮阳东方男科医院割包皮值得信赖濮阳东方医院治阳痿口碑好价格低,濮阳东方医院看男科病评价很不错,濮阳东方妇科医院收费公开,濮阳市东方医院口碑很好价格低,濮阳东方妇科医院做人流口碑比较好,濮阳东方医院看阳痿评价很高,濮阳东方医院看男科病专业

WASHINGTON, Dec. 2 (Xinhua) -- The U.S. Justice Department Friday approved Google's 400 million dollar acquisition of Admeld, a company that provides an online advertising platform for publishers.The Justice Department concluded that it was "not likely to substantially lessen competition in the sale of display advertising."Google operates the largest Internet search engine in the world and one of the largest display advertising platforms. It had revenues of about 29 billion dollars in 2010, most of which came from ads revenue.Admeld, with annual revenue of 30 million dollars, offers technology services to Internet publishers that help them boost revenue by optimizing ads display from hundreds of sources.Google is expected to grab 9.3 percent of online display advertising spending in the U.S. this year, up from 8.6 percent last year, making it the No. 3 provider, according to the digital intelligence company Emarketer.The No. 1 position will be taken by Facebook with its share increased to 16 percent up from 12 percent a year ago, while Yahoo! will slip slightly to 13 percent, said Emarketer.

WASHINGTON, Nov. 11 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved HEMACORD, the first licensed hematopoietic progenitor cells-cord cell therapy.HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the blood forming system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders."The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants. The other two are bone marrow and peripheral blood. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and mature. When the mature cells move into the bloodstream they can partially or fully restore the number and function of many blood cells, including immune function.

BEIJING, Nov. 30 (Xinhua) -- China's efforts to fight AIDS are impressive and its experience can be shared, according to Michel Sidibe, executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS)."We have seen progress in terms of new infections. The number of people going into treatment is increasing and the mortality rate is going down very quickly in China," Sidibe said during an interview with Xinhua on Wednesday.Sidibe said he was impressed by the country's political leadership and commitment to controlling AIDS.According to UNAIDS, the country has reported a 60-percent reduction in deaths due to AIDS over the past eight years.New HIV infection cases in China have been reduced from 70,000 people annually in 2005 to around 48,000 in 2011, according to the country's health department."However, China's success will not only be measured by what it has done for the Chinese people," Sidibe said.China has successful experience in reducing new HIV infections among intravenous drug users, which can be shared with the rest of the world, particularly east Europe and south Asia where HIV infections among drug abusers is a major challenge, he said.Sidibe suggested that the country should work with the rest of the developing world, particularly Africa, in fighting AIDS.A partnership between China and Africa will make a "big, big difference" in reducing AIDS mortality rates and introducing new technology and perspectives in Africa, said the official who had worked for UN in several African countries for more than two decades.Admitting the challenges of funding AIDS control programs during the current global economic downturn, Sidibe called for global solidarity and increasing shared responsibilities among countries."It is a critical moment now. It is not a time to stop investment but to redouble our efforts, to make sure that we will continue to make progress in the fight against HIV," Sidibe said."Getting to Zero" has been chosen as the main theme of World AIDS Day for the next five years, referring to UNAIDS' vision of "zero new HIV infections, zero discrimination and zero AIDS-related deaths."Sidibe met with Li Congjun, president of the Xinhua News Agency, on Wednesday before the interview. The agency has launched a global media campaign in cooperation with UNAIDS to raise public awareness about HIV/AIDS."The partnership (with Xinhua) is not only about writing news about HIV. It is about helping people to change their attitude and make decisions to help protect themselves," Sidibe said.

WASHINGTON, Dec. 12 (Xinhua) -- British scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth. The findings, published Monday in the U.S. journal Cancer Cell, reveal how cancer cells grow faster by producing their own blood vessels.Cancer cells gain the nutrients they need by producing proteins that make blood vessels grow, helping deliver oxygen and sugars to the tumor. These proteins are vascular growth factors like VEGF -- the target for the anti-cancer drug Avastin. Making these proteins requires the slotting together of different parts of genes, a process called splicing.Scientists at the University of West England and the University of Bristol discovered that mutations in one specific cancer gene can control how splicing is balanced, allowing a master switch in the cell to be turned on. This master switch of splicing makes cancer cells grow faster, and blood vessels to grow more quickly, as they alter how VEGFs are put together.In experimental models, the researchers found that by using new drugs that block this master switch they prevented blood vessel growth and stopped the growth of cancers."The research clearly demonstrates that it may be possible to block tumor growth by targeting and manipulating alternative splicing in patients, adding to the increasingly wide armory of potential anti-cancer therapies," the authors said.

BEIJING, Nov. 28 (Xinhuanet) -- A majority of the emergency hospitalizations for bad events related to medication use in old U.S. adults stem from four common medications, according to a new study in the New England Journal of Medicine Monday.The study was conducted by researchers from the Centers for Disease Control and Prevention of U.S.There are nearly 100,000 emergency hospitalizations for adverse drug events in older Americans, says researcher Daniel S. Budnitz, MD, MPH, director of the CDC's Medication Safety Program.And the four types of medication -- two for diabetes and two blood-thinning agents -- account for two-thirds of those drug-related emergency hospitalizations. They most often cited: warfarin (Coumadin, Jantoven); insulin; antiplatelet drugs such as aspirin and clopidogrel (Plavix); oral hypoglycemic agents."Both blood thinners and diabetes medicines are critical drugs that can be lifesaving," Budnitz says.However, he says that ''these are medications that you do need to pay attention to," being sure the dose and timing are correct, among other measures.